Press Releases

Elto Pharma Receives Notice of Allowance in Canada for Patent Covering Use of Eltoprazine to Treat non-ADHD Cognitive Impairment

NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Elto Pharma, Inc., a specialty pharmaceutical, clinical-stage wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) advancing eltoprazine into a Phase 2b human clinical trial for the treatment of the orphan indication Parkinson's disease levodopa-induced dyskinesia (PD-LID), today announced that the Canadian Intellectual Property Office recently issued a Notice of Allowance for a patent application entitled "Use of Eltoprazine for Improvement of Symptoms of Cognitive Impairment Associated with non-ADHD Neurological and Mental Disorders" covering the use of eltoprazine to treat a range of non-ADHD neurological and mental conditions, including Parkinson's disease and Alzheimer's disease. Upon issuance, the patent will extend exclusivity protection for eltoprazine in Canada for the treatment of non-ADHD cognitive impairment into 2029.

"Eltoprazine has a unique pharmacodynamic profile and holds promise in exploring its effect on cognitive impairment in a variety of neurological and neuropsychiatric conditions. It has shown statistically significant improvement of cognition in a proof of concept study of adult patients with ADHD. This suggests that it may have benefits for cognition in other neuropsychiatric disorders that can be evaluated in clinical trials," said Dr. Paula Trzepacz, Elto Pharma's Chief Medical Advisor. "As we build the clinical data package around eltoprazine in our Phase 2b PD-LID program, we will consider including secondary endpoints that assess relevant aspects of cognition."

About Elto Pharma, Inc.

Elto Pharma, Inc. is developing eltoprazine, an oral small molecule 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), aggression in Alzheimer's disease and adult attention deficit hyperactivity disorder (adult ADHD). Eltoprazine has been evaluated in over 680 human subjects to date, was well-tolerated and showed promising efficacy results in both cognitive and movement disorders. Eltoprazine has received orphan drug designation (ODD) from the US FDA for the treatment of PD-LID.

Eltoprazine was originally developed by Solvay (now Abbvie) for aggression-related indications. The eltoprazine program was out-licensed to PsychoGenics, Inc. (PGI). PGI licensed eltoprazine to Amarantus in 2014 after a successful proof-of-concept trial in PD-LID.

In April 2017, Amarantus incorporated the wholly-owned subsidiary Elto Pharma, Inc. for the purpose of raising capital to finance the further clinical development of eltoprazine.

About Amarantus Bioscience Holdings, Inc.

Amarantus Bioscience Holdings (AMBS), a JLABS alumnus company, is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS' wholly-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer's aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired the rights to the Engineered Skin Substitute program, a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by AMBS' wholly-owned subsidiary Cutanogen Corporation. AMBS' wholly-owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor ("MANF"). MANF Therapeutics, Inc. is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company's Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS' proprietary discovery engine PhenoGuard. The Company also re-acquired rights to the Alzheimer's blood diagnostic LymPro Test , MSPrecise and NuroPro.

For further information please visit, or connect with the Amarantus on Facebook, LinkedIn, Twitter and Google+.

Amarantus Investor and Media Contact:

Howard Gostfrand

American Capital Ventures, Inc.

Office: 305-918-7000


Source: Amarantus Bioscience Holdings, Inc.

Primary Logo

Source: Amarantus Bioscience Holdings, Inc.